# Pediatric Cancer Research Foundation

Grantmaking public charity, Irvine, California. EIN 95-3772528.

Source: the foundation’s own IRS returns, read November 20, 2026, as shown by the Alleviate Index. https://sites.alleviate.org/index/funder/pediatric-cancer-research-foundation-953772528

## Applications

Schedule I of Form 990 lists the grants made, not how to apply, so this return does not say whether Pediatric Cancer Research Foundation accepts applications.

## What it gave

- Grants paid: $1,695,918 (Year ending June 2025)
- Grants listed: 15 (To organizations, on that return)
- Typical grant: $45,000 (Half fall between $31,000 and $100,000)

- June 2025: Grants paid $1,695,918; Grants listed 15
- June 2024: Grants paid $914,813; Grants listed 14

From Schedule I of its Form 990 returns for the years ending June 2024 to June 2025.

## What it funds, and where

- Focus, by share of linked grant dollars: Medical research 70%, Health care 28%, Human services 1%
- Where it gave, by number of grants: California 12, New York 5, Massachusetts 2, Ohio 2, Maryland 2, Indiana 2, District of Columbia 2, North Carolina 1, Pennsylvania 1

## Recent grants to organizations

- NEW YORK MEDICAL COLLEGE (Valhalla, New York): $550,000, year ending June 2025. PEDIATRIC CANCER RESEARCH FOUNDATION LABORATORY AT NEW YORK MEDICAL COLLEGE
- [The V Foundation](https://sites.alleviate.org/index/org/the-v-foundation-133705951) (Cary, North Carolina): $204,000, year ending June 2025. CANCER RESEARCH
- MEMORIAL SLOAN KETTERING (New York, New York): $150,000, year ending June 2025. TOWARDS CURATIVE EPIGENETIC THERAPIES OF REFRACTORY PEDIATRIC SARCOMAS
- [City of Hope National Medical Center](https://sites.alleviate.org/index/org/city-of-hope-national-medical-center-951683875) (Duarte, California): $100,000, year ending June 2025. SINGLE-CELL DISSECTING OF HIGH-RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
- [Dana-Farber Cancer Institute](https://sites.alleviate.org/index/org/dana-farber-cancer-institute-042263040) (Boston, Massachusetts): $100,000, year ending June 2025. ADVANCING LIQUID BIOPSIES TO THE CLINIC FOR PATIENTS WITH EWING SARCOMA
- STANFORD (Palo Alto, California): $100,000, year ending June 2025. TARGETING MITOCHONDRIAL PATHWAYS IN PEDIATRIC AML
- JOHNS HOPKINS (Baltimore, Maryland): $100,000, year ending June 2025. TARGETING SHP2 AS A THERAPEUTIC STRATEGY IN FUSION-NEGATIVE RHABDOMYOSARCOMA
- UNIVERSITY OF CALIFORNIA SAN FRANCISCO (San Francisco, California): $45,000, year ending June 2025. A RISK STRATIFIED CLINICAL TRIAL FOR PATIENTS WITH NEWLY DIAGNOSED JUVENILE MYELOMONOCYTIC LEUKEMIA
- CHILDREN'S HOSPITAL LOS ANGELES (Los Angeles, California): $37,500, year ending June 2025. PRECLINIAL STUDY TO TRANSLATE THERAPY USING DNA HYPOMETHYLATING AGENTS FOR PEDIATRIC HIGH GRADE GLIOMAS
- CASE WESTERN (Clevenland, Ohio): $37,500, year ending June 2025. USE OF MR FINGERPRINTING FOR DETERMINING RESPONSE TO IMMUNOTHERAPY IN PEDIATRIC BRAIN TUMORS
- CHILDREN'S HOSPITAL LOS ANGELES (Los Angeles, California): $32,000, year ending June 2025. RESEARCH INTO MULTIDISCIPLINARY APPROACH TO SIGNIFICANTLY AND POSITIVELY IMPROVE THE QUALITY OF LIFE OF AND QUALITY OF CARE FOR CHILDREN AND YOUNG PEOPLE WITH CANCER
- [Hope for Henry Foundation](https://sites.alleviate.org/index/org/hope-for-henry-foundation-200244173) (Washington, District of Columbia): $30,000, year ending June 2025. REWARDING PEDIATRIC PATIENTS AND ELEVATING THEIR CARE
- INDIANA UNIVERSITY (Bloomington, Indiana): $27,000, year ending June 2025. DECODING METABOLIC DEPENDENCIES OF MPNSTS AND ITS MICROENVIRONMENT
- [Ronald McDonald House Charities of Southern California](https://sites.alleviate.org/index/org/ronald-mcdonald-house-charities-of-southern-california-953167869) (Los Angeles, California): $25,000, year ending June 2025. WILDFIRE RECOVERY FUNDING FOR FAMILIES OF CANCER PATIENTS AT THE LOS ANGELES RONALD MCDONALD HOUSE
- [Live for Liv Foundation](https://sites.alleviate.org/index/org/live-for-liv-foundation-272472834) (Westford, Massachusetts): $8,000, year ending June 2025. SUPPORTS CHILDREN AND FAMILIES DEALING WITH SERIOUS CONDITIONS
- NEW YORK MEDICAL COLLEGE (Valhalla, New York): $275,000, year ending June 2024. PEDIATRIC CANCER RESEARCH FOUNDATION LABORATORY AT NEW YORK MEDICAL COLLEGE
- MEMORIAL SLOAN KETTERING (New York, New York): $75,000, year ending June 2024. TOWARDS CURATIVE EPIGENETIC THERAPIES OF REFRACTORY PEDIATRIC SARCOMAS
- [City of Hope National Medical Center](https://sites.alleviate.org/index/org/city-of-hope-national-medical-center-951683875) (Duarte, California): $50,000, year ending June 2024. SINGLE-CELL DISSECTING OF HIGH-RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
- [Dana-Farber Cancer Institute](https://sites.alleviate.org/index/org/dana-farber-cancer-institute-042263040) (Boston, Massachusetts): $50,000, year ending June 2024. PROSPECTIVE VALIDATION OF A PROGNOSTIC LIQUID BIOPSY APPROACH FOR PEDIATRIC EWING SARCOMA
- STANFORD UNIVERSITY (Palo Alto, California): $50,000, year ending June 2024. TARGETING MITOCHONDRIAL PATHWAYS IN PEDIATRIC AML
- JOHNS HOPKINS UNIVERSITY (Baltimore, Maryland): $50,000, year ending June 2024. TARGETING SHP2 AS A THERAPEUTIC STRATEGY IN FUSION-NEGATIVE RHABDOMYOSARCOMA
- [Hope for Henry Foundation](https://sites.alleviate.org/index/org/hope-for-henry-foundation-200244173) (Washington, District of Columbia): $49,563, year ending June 2024. REWARDING PEDIATRIC PATIENTS AND ELEVATING THEIR CARE
- UCSF (San Francisco, California): $40,000, year ending June 2024. TACL2020-004: A RISK STRATIFIED CLINICAL TRIAL FOR PATIENTS WITH NEWLY DIAGNOSED JUVENILE MYELOMONOCYTIC LEUKEMIA
- CHILDREN'S HOSPITAL OF LOS ANGELES (Los Angeles, California): $37,500, year ending June 2024. PRECLINIAL STUDY TO TRANSLATE THERAPY USING DNA HYPOMETHYLATING AGENTS FOR PEDIATRIC HIGH GRADE GLIOMAS
- CASE WESTERN (Clevenland, Ohio): $37,500, year ending June 2024. USE OF MR FINGERPRINTING FOR DETERMINING RESPONSE TO IMMUNOTHERAPY IN PEDIATRIC BRAIN TUMORS

Method and sources: https://sites.alleviate.org/index/method#funders
